InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: geocappy1 post# 204649

Saturday, 01/31/2015 5:33:48 PM

Saturday, January 31, 2015 5:33:48 PM

Post# of 346359

PCYC was at .79 at one time and $170 per share within 4 years.



I agree Geo. The pps is not relevant and you point out exactly why its not relevant at this time.

Getting bavituximab and PS Targeting into the hands of hundreds and thousands will move this share price like no other biotech ever before and will dwarf the spikes in price made by PCYC.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News